Simoa: Novel Insights in High-Sensitivity Immunoassays

Simoa, short for Single Molecule Array, is a digital immunoassay technology that can detect proteins at concentrations roughly a thousand times lower than standard lab methods. Where a conventional ELISA might bottom out at tens of picograms per milliliter, Simoa routinely reaches the low femtomolar range, picking up individual protein molecules one at a time. That leap in sensitivity has opened the door to measuring biomarkers in blood that were previously detectable only in cerebrospinal fluid, and it is reshaping how researchers think about early detection in neurology, oncology, and infectious disease.

How Single Molecule Counting Works

Traditional immunoassays work by analogy to a crowd: you measure how loud the room is and infer how many people are in it. Simoa flips the approach. Instead of measuring a pooled signal from all bound molecules at once, it isolates individual protein molecules on microscopic beads and reads them one at a time, essentially counting heads in the crowd directly.

The process starts with antibody-coated paramagnetic beads that capture target proteins from a sample. After a sandwich immunocomplex forms on each bead, an enzyme label is attached. The beads are then loaded into an array of femtoliter-sized microwells, each just large enough to hold a single bead. The wells are sealed with oil, trapping any enzymatic product in a tiny volume so that even one enzyme molecule generates a bright fluorescent signal. At low target concentrations, the statistics work out so that each well contains either zero or one labeled molecule, turning the readout into a binary yes-or-no for every well. Counting the fraction of “on” wells gives a direct digital measurement of concentration.

The efficiency of this capture-and-detect process is high. Careful measurements of single-enzyme kinetics on the beads showed that the efficiency of capturing and detecting enzyme exceeded 70%, meaning most labeled molecules actually get counted rather than lost in the noise.¹ At higher concentrations, where many wells contain a labeled bead, the system switches to an analog mode similar to a standard immunoassay. This dual digital-analog approach gives Simoa a wide dynamic range, from single molecules up to clinically relevant high-concentration samples.²

How Much More Sensitive Is It, Really?

The numbers are striking and have been replicated across multiple independent head-to-head comparisons. For neurofilament light chain (NfL), a protein released when nerve fibers are damaged, a three-way comparison found that Simoa achieved a detection limit of 0.62 pg/mL. The electrochemiluminescence assay it was tested against needed 15.6 pg/mL, and the conventional ELISA needed 78 pg/mL.³ That makes Simoa roughly 25 times more sensitive than the electrochemiluminescence platform and over 100 times more sensitive than ELISA for that particular analyte.

A more recent study comparing Simoa to a high-sensitivity ELISA and a fully automated chemiluminescent immunoassay reported manufacturer-stated lower limits of detection of 0.062 ng/L for Simoa, 0.40 ng/L for the high-sensitivity ELISA, and 0.71 ng/L for the automated immunoassay.⁴ The gap between Simoa and the newer automated platforms is narrower than the gap with classic ELISA, but Simoa consistently sits at the most sensitive end of the spectrum.

Why does a factor-of-25 or factor-of-100 improvement matter practically? Because many disease-relevant proteins exist in blood at concentrations that sit below the floor of conventional assays. If your method can only see down to 78 pg/mL and the protein you need to measure circulates at 5 pg/mL, you get a reading of zero regardless of whether the patient has early-stage disease or is perfectly healthy. Simoa crosses that threshold and turns a previously invisible signal into a quantifiable one.

Neurology Has Been the Biggest Beneficiary

The brain is separated from the bloodstream by the blood-brain barrier, which means proteins shed by injured neurons get diluted roughly 40-fold by the time they reach blood compared to cerebrospinal fluid.⁵ For decades, this meant that blood-based neurological biomarkers were essentially off the table; you either did a spinal tap or you went without. Simoa changed that calculus by making blood-based measurement of several key brain proteins reliable enough for clinical research and, increasingly, for clinical decisions.

Neurofilament Light Chain in Multiple Sclerosis

NfL has become one of the best-studied applications of Simoa. In multiple sclerosis, elevated NfL in blood reflects ongoing nerve-fiber damage and correlates with disease activity. A cross-sectional study comparing Simoa with a high-sensitivity ELISA for serum NfL in MS patients found a strong correlation between the two platforms and no systematic bias, suggesting the results are interchangeable for both clinical and research purposes.⁶ The practical upside is that neurologists can track NfL over time with a routine blood draw rather than repeated lumbar punctures, making it far easier to monitor whether a treatment is controlling disease activity.

Phosphorylated Tau and Alzheimer’s Disease

Blood-based Alzheimer’s diagnosis has been one of the hardest targets in biomarker research. Simoa assays for phosphorylated tau (p-tau) isoforms have shown strong performance in distinguishing Alzheimer’s patients from healthy controls. A comparison of six Simoa assays targeting three p-tau variants found that the best-performing assays achieved diagnostic accuracy above 0.93 on a 0-to-1 scale, with some reaching 0.995.⁷ Those numbers approach the performance of cerebrospinal fluid biomarkers and PET brain scans, which is remarkable for a blood test. Not all p-tau isoforms performed equally well, though. The assay for one variant lagged behind the others, a reminder that the biology of the target matters as much as the sensitivity of the platform.

Traumatic Brain Injury

In traumatic brain injury, speed matters. Simoa has been used to track multiple brain-injury proteins in plasma simultaneously. One study found that plasma GFAP and tau measured by Simoa on the day of injury could distinguish complicated mild TBI from controls with high accuracy.⁸ A separate evaluation of a Simoa four-plex assay that measured GFAP, UCH-L1, NfL, and tau simultaneously in TBI patients found that all four biomarkers had meaningful diagnostic accuracy for identifying patients with abnormal head CT findings.⁹ The appeal here is not just sensitivity but simultaneous measurement: different brain cell types release different proteins when injured, and measuring all four at once paints a more complete picture of what kind of damage occurred.

Cytokines, Cancer, and Infectious Disease

Outside neurology, Simoa has found traction wherever the proteins of interest circulate at vanishingly low levels. Cytokines are a prime example. These immune-signaling molecules play central roles in inflammation, autoimmune disease, and cancer, but in healthy people they often circulate at sub-picogram-per-milliliter concentrations, well below the detection floor of standard ELISA. Simoa-based cytokine assays allow detection at these levels, providing reference profiles of ten cytokines in healthy human serum that were previously unmeasurable.¹⁰ A comparative evaluation of several ultrasensitive immunoassay technologies confirmed that Simoa was among the most sensitive platforms for sub-pg/mL cytokine quantification.¹¹

In oncology, researchers have adapted Simoa to detect tumor-derived extracellular vesicles directly in blood, essentially tiny membrane-bound packages shed by cancer cells. One study developed Simoa assays for colorectal cancer that used pairs of vesicle surface markers to detect tumor-derived vesicles with high sensitivity while avoiding false signals from free-floating proteins.¹² In lung cancer, a Simoa-based assay targeting PD-L1 on circulating tumor-derived vesicles distinguished patients with PD-L1-positive tumors from PD-L1-negative patients, with a sensitivity above 90%.¹³ PD-L1 status currently guides decisions about immunotherapy, but it typically requires tissue from a biopsy or surgical sample. A reliable blood-based alternative would be clinically valuable, especially for patients whose tumors are hard to biopsy. More recently, assays measuring EGF receptor on extracellular vesicles have been developed using Simoa, expanding the list of tumor markers that can be tracked noninvasively in plasma.¹⁴

Infectious disease applications emerged dramatically during the COVID-19 pandemic. Simoa assays were used to track SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens directly in plasma, profiling how viral protein levels changed over the course of severe disease.¹⁵ Even before the pandemic, a Simoa-based digital p24 antigen assay for HIV demonstrated sensitivity comparable to nucleic acid amplification tests, the gold standard for detecting acute HIV infection, but in a simpler, lower-cost, fully automated format.¹⁶ The implication is significant: protein-based immunoassays are cheaper and logistically simpler than molecular tests, and if they can match the sensitivity, they become practical options in resource-limited settings.

What Can Go Wrong Before the Assay Even Runs

Ultrasensitive detection is a double-edged sword. When your instrument can detect individual molecules, it can also detect problems that never registered on less sensitive platforms. Pre-analytical variables, everything that happens to a sample between the blood draw and the assay, become critical.

Hemolysis is one of the most common pre-analytical headaches. When red blood cells break open during collection or processing, the released contents can interfere with protein measurements. A study evaluating Simoa measurements of several neurological biomarkers found that high levels of hemolysis inflated NfL readings by up to roughly 30%, while p-tau181 remained largely unaffected. Amyloid-beta 40, amyloid-beta 42, and GFAP showed modest interference at intermediate hemolysis levels.¹⁷ The inconsistency across analytes is the frustrating part: you cannot simply flag a hemolyzed sample as unreliable for everything; some markers are affected and others are not.

Freeze-thaw cycles and delays before centrifugation also matter. A global consortium recently assessed multiple pre-analytical variables including tube type, centrifugation timing, storage delays, and freeze-thaw effects specifically for Simoa-measured biomarkers, working toward a standardized sample-handling protocol for blood-based Alzheimer’s diagnostics.¹⁸ Reassuringly, for cytokines at least, plasma appears stable over three freeze-thaw cycles.¹⁹ But the broader lesson is that each analyte has its own vulnerability profile, and standardized handling protocols need to be validated marker by marker.

Blood is also a biochemically noisy environment. Heterophilic antibodies and other interfering molecules can create spurious signals. One advantage of ultrasensitive assays is that samples can be diluted more heavily, which reduces the concentration of these interfering substances while still keeping the target analyte above the detection limit.²⁰ In other words, the extreme sensitivity buys you room to dilute away problems that would swamp a less sensitive method.

The Multiplexing Problem

Measuring several proteins simultaneously from one small blood sample is tremendously appealing, and Simoa multiplexing has already been applied clinically in settings like traumatic brain injury, as noted above. But multiplexing introduces its own set of complications, the biggest being cross-reactivity.

In a single-target assay, both the capture antibody and the detection antibody would need to bind the wrong protein for a false signal to appear, and the probability of that double mistake is vanishingly small. In a multiplexed assay, where multiple capture and detection antibodies share the reaction solution, only one cross-reactive binding event can generate a false signal. Unless this cross-reactivity is quantified and addressed during analysis, the measurements can become unreliable.²¹ Strategies to deal with this include sequential capture steps, where antibodies are added one at a time rather than all at once, and careful characterization of crosstalk between bead populations. Early multiplexed Simoa assays measuring four cytokines simultaneously achieved femtomolar detection limits but observed crosstalk on the order of 1 to 2% between bead subpopulations in the microwell array, which could inflate readings for low-abundance analytes when high-abundance targets are present nearby.²²

Why Antibody Selection Matters More Than You Might Think

Even with the world’s most sensitive instrument, the assay is only as good as the antibodies it uses. A study that compared six antibodies spanning a four-log range of binding strengths found that Simoa assay performance was most strongly governed by how slowly the detection antibody fell off its target. The fluorescent signals were highest when the detection antibody’s dissociation rate was extremely low, below a threshold of one event per hundred thousand seconds. The capture antibody was more forgiving, but still needed a reasonably slow off-rate. Interestingly, how quickly the antibodies bound their target in the first place, the on-rate, did not meaningfully affect performance for either the capture or detection step.²³

This makes intuitive sense when you think about the workflow. The beads go through multiple wash steps and then get sealed into microwells. If the detection antibody tends to let go of the target molecule easily, the signal disappears before the well gets sealed. Speed of initial binding can be compensated for by giving the reaction enough time, but a weak grip cannot be fixed after the fact. For labs developing new Simoa assays, this finding is a practical guide: screen antibody candidates by off-rate first, and do not waste time optimizing other parameters until you have a pair that holds on tightly.

Shrinking the Instrument

The current Simoa platform is a benchtop instrument with automated liquid handling, designed for centralized research and clinical laboratories. It is not something you would carry to a rural clinic or a battlefield triage tent. But several groups are working to translate the core principle of single-molecule digital counting into portable, point-of-care formats.

One approach uses digital microfluidics, which manipulates tiny droplets on disposable chips rather than relying on the bulky optics and robotics of the standard Simoa platform. Researchers have demonstrated a semi-automated system using roll-to-roll manufactured microwell chips that can perform digital target counting at a fraction of the size and cost of current lab instruments.²⁴ A separate line of development is pursuing a bioelectronic approach, where single-molecule detection occurs on a transistor-based sensor small enough to fit in the palm of a hand. These devices, still at an intermediate stage of development, aim for false-positive and false-negative rates below 1 to 5%, with detection limits reaching down to just a few molecules of the target.²⁵

Neither approach has reached the market yet, and the engineering challenges are formidable. The sealed-femtoliter-well design that gives Simoa its sensitivity depends on precise optics and stable enzyme kinetics, both of which are harder to control in a stripped-down portable device. But the trajectory is clear: the field is moving toward making single-molecule sensitivity available outside the specialized laboratory. If and when that happens, the applications could range from bedside TBI screening in emergency departments to HIV screening in regions without access to molecular testing, problems where Simoa has already demonstrated the analytical capability but where the current instrument format does not fit the clinical workflow.